Enitociclib

N/A

Report date: 2024/02/05 20:04:22
NME

Base Information

Drug NameEnitociclib
Drug Alias NameBAY-1251152VIP-152
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsPositive transcriptional elongation factor B inhibitors
TargetsCyclin-dependent kinase 9Positive transcriptional elongation factor B
Therapy Area/IndicationsRichter's SyndromeHematologic NeoplasmsLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandGermany +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteVincerx Pharma Inc
Inactive CompaniesBayer AG
Active IndicationsHematologic NeoplasmsLymphoma, Non-HodgkinLymphoma +[4] 
Inactive IndicationsRichter's SyndromeLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A